Utility of prodrome diagnostic tests

June 15, 2016

Dr. Dayan Goodenowe describes the utility of prodrome diagnostic tests for population-based cancer screening at the Cancer Diagnostics Conference & Expo in Rome, Italy

On June 13, 2016, Dr. Dayan Goodenowe, founder of Prodrome Sciences Inc., presented research results supporting the use of prodrome-based diagnostic tests for population-based screening of colorectal, pancreatic, and ovarian cancers at the Cancer Diagnostics Conference & Expo in Rome, Italy.

The prodrome state of a disease is the unhealthy state that precedes and causes a disease to occur. Although there are no obvious disease symptoms in the prodrome, biochemical systems in the body are no longer functioning properly. Persons that test positive for a disease prodrome have an elevated risk of getting that disease whereas persons that test negative have a reduced risk of getting that disease.

Disease prodromes can be detected in a small sample of blood. Detecting cancer prodromes is a safe and effective way to screen large populations to identify those persons with an elevated disease risk, but do not know it. Such persons can then undergo additional testing and monitoring to ensure that, if a cancer has developed, it can be detected at the earliest possible stage and when available treatment options are most effective.

Dr. Goodenowe is the inventor of several patents relating to the diagnosis of cancer. 

Contact us for more information.

Keep in touch

©2020 Prodrome Sciences Inc.